Aging (Albany NY). 2026 Feb 6;18(1):45-59. doi: 10.18632/aging.206352. Online ahead of print.ABSTRACTBACKGROUND: Interleukin-6 (IL6) signaling plays a key role in inflammation and cardiovascular disease, but its causal effect on long-term mortality remains unclear. We aimed to assess whether genetic
Can J Physiol Pharmacol. 2026 Feb 26. doi: 10.1139/cjpp-2025-0245. Online ahead of print.ABSTRACTAcetylcholinesterase (AChE) inhibitors constitute a group of compounds that inhibit the enzyme AChE. Some of these that are used to treat Alzheimer's disease have been reported to have favourable cardiov
Bol Med Hosp Infant Mex. 2026;83(1):21-31. doi: 10.24875/BMHIM.25000061.ABSTRACTBACKGROUND: The relationship between abdominal fat depots and cardiometabolic risk among youth is inconclusive due to the cross-sectional nature of existing studies and limitations in assessment methods. In this study, w
Aging Dis. 2026 Feb 26. doi: 10.14336/AD.2025.1500. Online ahead of print.ABSTRACTAging proceeds heterogeneously across organs, making chronological age an inadequate measure of physiological decline. The concept of organ biological age (OBA) offers a refined framework to quantify organ-specific fun
No abstractJ Cardiopulm Rehabil Prev. 2026 Mar 1;46(2):77-78. doi: 10.1097/HCR.0000000000001032. Epub 2026 Feb 26.NO ABSTRACTPMID:41747082 | DOI:10.1097/HCR.0000000000001032
Science. 2026 Feb 26;391(6788):eadt1522. doi: 10.1126/science.adt1522. Epub 2026 Feb 26.ABSTRACTHigh-sugar diets cause human metabolic diseases, yet several bird lineages convergently adapted to feeding on sugar-rich nectar or fruits. We investigated the underlying molecular mechanisms in hummingbir
No abstractCirc Res. 2026 Feb 27;138(5):e328125. doi: 10.1161/CIRCRESAHA.126.328125. Epub 2026 Feb 26.NO ABSTRACTPMID:41747014 | DOI:10.1161/CIRCRESAHA.126.328125
No abstractCirc Res. 2026 Feb 27;138(5):e328021. doi: 10.1161/CIRCRESAHA.125.328021. Epub 2026 Feb 26.NO ABSTRACTPMID:41747013 | DOI:10.1161/CIRCRESAHA.125.328021
Circ Res. 2026 Feb 27;138(5):e326979. doi: 10.1161/CIRCRESAHA.125.326979. Epub 2026 Feb 26.ABSTRACTCardiometabolic diseases (CMDs) refer to a broad spectrum of interconnected disorders, including heart attack, obesity, diabetes, atherosclerosis, and metabolic dysfunction-associated steatohepatitis,
Diab Vasc Dis Res. 2026 Jan-Feb;23(1):14791641251407678. doi: 10.1177/14791641251407678. Epub 2026 Feb 26.ABSTRACTBackgroundCoronary heart disease (CHD) is a prevalent complication associated with type 2 diabetes mellitus (T2DM), and the incidence of T2DM with CHD has seen a steady rise over the pre
PLoS One. 2026 Feb 26;21(2):e0343023. doi: 10.1371/journal.pone.0343023. eCollection 2026.ABSTRACTBACKGROUND AND AIMS: This study aims to examine the association between dietary patterns, the atherogenic index of plasma (AIP), and cardiovascular risk factors in adults aged 40-70 years in southern Ir
PLoS One. 2026 Feb 26;21(2):e0333827. doi: 10.1371/journal.pone.0333827. eCollection 2026.ABSTRACTBACKGROUND: Insulin resistance (IR) is a significant risk factor for cardiovascular disease (CVD), yet practical biomarkers for long-term IR assessment are limited. The triglyceride glucose-waist-to-hei
Expert Rev Respir Med. 2026 Feb 26. doi: 10.1080/17476348.2026.2637202. Online ahead of print.ABSTRACTINTRODUCTION: Ideal respiratory health and chronic respiratory disease exist on a continuum. Between these two extremes lies an intermediate state of impaired respiratory health, characterized by cl
Cardiology. 2026 Feb 26:1-20. doi: 10.1159/000550762. Online ahead of print.ABSTRACTINTRODUCTION: Oscillatory breathing (OB) observed during cardiopulmonary exercise testing (CPX) is a critical phenomenon, especially in patients with heart failure. Patients with cardiovascular diseases with OB usual
ESC Heart Fail. 2026 Feb 26:xvag066. doi: 10.1093/eschf/xvag066. Online ahead of print.ABSTRACTAIMS: Cardiogenic shock (CS) represents an ominous complication of acute myocardial infarction (AMI) with mortality rate exceeding 50%. The aim of the study was to evaluate current management, outcomes and
No abstractKidney360. 2026 Feb 1;7(2):321-334. doi: 10.34067/KID.0000001029. Epub 2025 Nov 14.NO ABSTRACTPMID:41746789 | DOI:10.34067/KID.0000001029
No abstractKidney360. 2026 Feb 1;7(2):221-222. doi: 10.34067/KID.0000001159. Epub 2026 Feb 26.NO ABSTRACTPMID:41746784 | DOI:10.34067/KID.0000001159
No abstractJ Med Internet Res. 2026 Feb 26;28:e93193. doi: 10.2196/93193.NO ABSTRACTPMID:41746746 | DOI:10.2196/93193
JCI Insight. 2026 Feb 26:e200105. doi: 10.1172/jci.insight.200105. Online ahead of print.ABSTRACTMitochondrial dysfunction devastates the heart in major cardiovascular diseases, yet the mechanisms governing mitochondrial quality control remain elusive. We discovered that TIGAR (TP53-induced glycolys
Arch Cardiol Mex. 2025 Nov 28;95(Supl 1):1-178. doi: 10.24875/ACM.M25000099.ABSTRACTComprehensive cardiovascular rehabilitation and prevention programs (CVRhP-P) are the cornerstone for improving maximum exercise tolerance, reducing mortality, improving health-related quality of life, and reducing h
Clin Transl Med. 2026 Mar;16(3):e70621. doi: 10.1002/ctm2.70621.ABSTRACTBACKGROUND: Ageing is a significant risk factor for pathophysiological alterations in the heart, but the intrinsic mechanisms by which these occur have yet to be fully elucidated. Purinergic 2×7 receptor (P2X7R) is important for
Hepatology. 2026 Feb 25. doi: 10.1097/HEP.0000000000001726. Online ahead of print.ABSTRACTBACKGROUND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a critical pathological stage that can progress to liver fibrosis and hepatocellular carcinoma, and its development is closel
Mol Divers. 2026 Feb 26. doi: 10.1007/s11030-025-11455-5. Online ahead of print.ABSTRACTDiabetes is a chronic medical disorder caused by insufficient production of the hormone insulin by the pancreas. Although there are various treatment options available for controlling diabetes, including non-pept
Int J Hematol. 2026 Feb 26. doi: 10.1007/s12185-026-04181-7. Online ahead of print.ABSTRACTQuizartinib is an oral, once-daily, highly potent and selective second-generation, type II FMS-like tyrosine kinase 3 (FLT3) inhibitor, approved for the treatment of newly diagnosed and relapsed/refractory (R/
